Drug or intervention
Ticagrelor Clinical Trials
Studies that test Ticagrelor, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 83ST Elevation Myocardial Infarction
STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT
Primary percutaneous coronary intervention (PCI) is the preferred revascularization strategy for patients with acute ST-segment elevation myocardial infarction (STEMI).
- Trial name
- STARS DAPT (NCT05785897)
- Testing
- Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation
- Where
- 2 sites in Switzerland
- Volunteers
- 350 people
- Sponsor
- IGLESIAS Juan Fernando
Coronary Arterial Disease (CAD)
The Switching Antiplatelet-9 (SWAP-9) Study
The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).
- Trial name
- SWAP-9 (NCT06588595)
- Testing
- Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Coronary Artery Disease, Acute Coronary Syndromes
Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCI
This is a randomized, open-label, active-controlled, non-inferiority clinical trial (the ASPIRE-LD trial) conducted in China. It aims to compare the efficacy and safety of low-dose aspirin (50 mg once daily) versus standard-dose…
- Conditions
- Coronary Artery Disease, Acute Coronary Syndromes, Chronic Coronary Syndrome, Percutaneous Coronary Intervention
- Trial name
- ASPIRE-LD (NCT07846462)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- China
- Volunteers
- 2,640 people
- Sponsor
- Jilin University
Coronary Artery Disease
OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation
Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by intravascular imaging (IVUS or OCT)…
- Trial name
- OPTIMIZE-APT (NCT05418556)
- Testing
- aspirin
- Where
- 33 sites in South Korea
- Volunteers
- 3,944 people
- Sponsor
- Asan Medical Center
Intracranial Aneurysm
A Multicenter Prospective Study of New Flow Diverter Stent on the Treatment of Intracranial Aneurysms in China
Intracranial aneurysm, as a common cerebrovascular disease, has a variety of treatment methods, including surgical treatment and endovascular treatment.
- Trial name
- APRESENT (NCT07821957)
- Testing
- Novel Flow Diverter Stent
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Beijing Tiantan Hospital
Cardiac Surgery
Ticagrelor Hemoadsorption Using Cytosorb® for Reduction of Bleeding During Cardiac Surgery
Cardiac surgery is at high risk of intraoperative bleeding. Inhibitors of the P2Y12 platelet receptor, such as ticagrelor, are recommended in patients with acute coronary stroke (ACS) to reduce the incidence of major…
- Trial name
- TICAdSORB (NCT07822620)
- Testing
- Device: Cytosorb hemoadsorption
- Where
- France
- Volunteers
- 232 people
- Sponsor
- University Hospital, Rouen
Chronic Coronary Syndrome
Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease
This is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication (PROBE design), comparing one-month dual antiplatelet therapy (DAPT) with low-dose ticagrelor (60 mg BID) followed by ticagrelor…
- Trial name
- STELAR (NCT07080684)
- Testing
- Ticagrelor 60 mg, clopidogrel 75 mg
- Volunteers
- 1,000 people
- Sponsor
- University of Messina
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Among aneurysmal subarachnoid hemorrhage (aSAH) survivors, ischemic injuries such as peri procedural thromboembolic events (TEE) and delayed cerebral ischemia (DCI) represent the most important disabling complications.
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia, Endovascular Procedure
- Trial name
- TALISCHER-SAH (NCT07821008)
- Testing
- Experimental group: ticagrelor
- Where
- 7 sites in France
- Volunteers
- 274 people
- Sponsor
- University Hospital, Toulouse
Peripheral Arterial Disease (PAD), Amputation
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore…
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- NCT07613840
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 484 people
- Sponsor
- Massachusetts General Hospital
Ischemic Stroke, Vertebral Artery Stenosis
Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis
Posterior circulation stroke accounts for 20% of all ischemic stroke. Approximately one quarter of posterior circulation strokes are due to stenosis in the vertebral artery and basilar artery.
- Trial name
- VISTA (NCT05885932)
- Testing
- Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor, Aspirin and clopidogrel or ticagrelor, mono anti-platelet therapy
- Where
- China
- Volunteers
- 472 people
- Sponsor
- Xuanwu Hospital, Beijing
Completed, with results posted
All 98Hemorrhage, Surgical, Blood Loss, Surgical
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Prospective, multi-center, double-blind, randomized pivotal trial to evaluate the safety and effectiveness of the DrugSorb-Antithrombotic Removal (ATR) system for intraoperative removal of ticagrelor in patients undergoing urgent…
- Conditions
- Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
- Trial name
- STAR-T (NCT04976530)
- Testing
- DrugSorb-ATR system
- Where
- 29 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- CytoSorbents, Inc
Myocardial Infarction, Thrombosis
CES1 Crossover Trial of Clopidogrel and Ticagrelor
The purpose of this investigation is to evaluate when genetic variation in the carboxylesterase 1 (CES1) gene influences antiplatelet therapy response, as assessed by ex vivo platelet aggregometry, in healthy participants treated…
- Conditions
- Myocardial Infarction, Thrombosis, Platelet Dysfunction
- Trial name
- NCT03161678
- Testing
- Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Coronary Artery Disease, Clopidogrel Resistance
The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models
The study purposed to learn how clopidogrel-based antiplatelet treatment for preventing adverse cardiovascular events after ePCI works in chronic coronary artery disease when guided by personal genetic characteristics for drug…
- Conditions
- Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac Events
- Trial name
- NCT06665919
- Testing
- CYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
- Where
- 4 sites in Georgia
- Volunteers
- 283 people
- Sponsor
- Vistamedi Ltd.
Acute Coronary Syndrome
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
Heart attacks are usually caused by clots in a coronary artery, depriving the heart muscle of blood. Platelets are the main type of blood cell causing clots to form and physicians typically give a combination of two anti-platelet…
- Trial name
- WILLOW TREE (NCT03869268)
- Testing
- Aspirin, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida